Future target molecules in antiglaucoma therapy: TGF-β may have a role to play

Ophthalmic Research

Volumn 43, Issue 1, 2009, Pages 1-10

  Agarwal, Renu ^a   Agarwal, Puneet ^b  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Extracellular matrix turnover; Glaucoma; Transforming growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE RECEPTOR ANTAGONIST; GELATINASE A; GELATINASE B; GLITAZONE DERIVATIVE; GW 788388; HALOFUGINONE; IMATINIB; LERDELIMUMAB; LOSARTAN; PEPTIDE APTAMER; PIRFENIDONE; SMALL INTERFERING RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

AQUEOUS HUMOR FLOW; DISEASE COURSE; DRUG PROTEIN BINDING; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; HYALINE DEGENERATION; INTRAOCULAR PRESSURE; KIDNEY FIBROSIS; MOLECULAR DYNAMICS; NONHUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SCAR FORMATION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; TURNOVER TIME; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; TRANSFORMING GROWTH FACTOR BETA;

EID: 70349890473     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000246571     Document Type: Review

References (110)

1. Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
2. Tomarev SI: Eyeing a new route along an old pathway. Nat Med 2001; 7: 294-295.
3. Morrison JC, Acott TS: Anatomy and physiology of aqueous humor outflow; in Morrison JC, Pollack IP (eds): Glaucoma Science and Practice. New York, Thieme Medical Publishers, 2003, pp 34-41.
4. Lutjen-Drecoll E: Importance of trabecular meshwork changes in the pathogenesis of primary open-angle glaucoma. J Glaucoma 2000; 9: 417-418.
5. Segawa K: Electron microscopic changes in the trabecular tissue in primary open angle glaucoma; Bellows JG (eds): Glaucoma: Contemporary International Concepts. New York, Masson, 1979, pp 17-23.
6. Rohen JW, Linner E, Witmer R: Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res 1973; 17: 19-31.
7. Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW: Quantitative analysis of plaque material in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res 1986; 42: 443-455. (Pubitemid 16121084)
8. Rohen JW, Lütjen-Drecoll E, Flügel C, Meyer M, Grierson I: Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res 1993; 56,683-692.
9. Knepper PA, Goossens W, Hvizd M, Palmberg PF: Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1996; 37: 1360-1367.
10. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM: Human trabecular meshwork organ culture: morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci 1988; 29: 90-100.
11. Rohen JW, Witmer R: Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Graefes Arch Clin Exp Ophthalmol 2004; 183: 251-266.
12. Lütjen-Drecoll E: Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res 1998; 18: 91-119.
13. Babihayev MA, Brodshaya JW: Fibronectin detection in drainage outflow system of human eyes in ageing and progressing of open angle glaucoma. Mech Ageing Dev 1989; 47: 145-157.
14. Maepea O, Bill A: Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res 1992; 65: 879-883.
15. Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM: Calculations of flow resistance in the juxtacanalicular meshwork. Invest Ophthalmol Vis Sci 1986; 27: 1741-1750.
16. Murphy CG, Johnson M, Alvarado JA: Juxtacanalicular tissue in pigmentary and primary open angle glaucoma the hydrodynamic role of pigment and other constituents. Arch Ophthalmol 1992; 110: 1779-1785.
17. Gong H, Ruberti J, Overby D, Johnson M, Freddo TF: A new view of the human trabecular meshwork using quick-freeze, deepetch electron microscopy. Exp Eye Res 2002; 75: 347-358.
18. Chaudry HA, Dueker DK, Simmons RJ, Bellows AR, Grant WM: Scanning electron microscopy of trabeculectomy specimens in open-angle glaucoma. Am J Ophthalmol 1979; 88: 78-92.
19. Dueker DK: Surgical specimens in open-angle glaucoma. Ann Ophthalmol 1980; 12: 1070-1075.
20. Vinuesa JM, Rodríguez ML, Vázquez R, Barahona JM, Marcos M: Estudio de la malla trabecular con microscopía electrónica de barrido en el ojo normal y en el glaucoma crónico simple. Arch Soc Esp Oftal 1982; 42: 105-115.
21. Potau JM, Canals M, Costa J, Merindano MD, Ruano D: Obstruction of trabecular orifices in primary open-angle glaucoma. Eur J Anat 2002; 6: 75-81.
22. Quigley HA, Addicks EM: Scanning electron microscopy of trabeculectomy specimens from eyes with open-angle glaucoma. Am J Ophthalmol 1980; 90: 854-857.
23. Maglio M, McMahon C, Hoskins D, Alvarado J: Potential artifacts in scanning electron microscopy of the trabecular meshwork in glaucoma. Am J Ophthalmol 1980; 90: 645-653.
24. Gieser DK, Tanenbaum M, Smith ME, Kass MA, Christy EN, Friesen H, Otterlei O, Becker B: Amorphous coating in open-angle glaucoma. Am J Ophthalmol 1981; 92: 130-132.
25. Overby D, Gong H, Qiu G, Freddo TF, Johnson M: The mechanism of increasing outflow facility during washout in the bovine eye. Invest Ophthalmol Vis Sci 2002; 43: 3455-3464.
26. Johnson M: What controls aqueous humor outflow resistance? Exp Eye Res 2006; 82: 545-557.
27. Sit AJ, Coloma FM, Ethier CR, Johnson M: Factors affecting the pores of the inner wall endothelium of Schlemm's canal. Invest Ophthalmol Vis Sci 1997; 38: 1517-1525.
28. Ethier CR, Coloma FM, Sit AJ, Johnson M: Two pore types in the inner wall endothelium of Schlemm's canal. Invest Ophthalmol Vis Sci 1998; 39: 2041-2048.
29. Nishida K, Sotozono C, Adachi W, Yamamoto S, Yokoi N, Kinoshita S: Transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA expression in human cornea. Curr Eye Res 1995; 14: 235-241.
30. Yamashita H: Functions of the transforming growth factor-β superfamily in eyes. J Jpn Ophthalmol Soc 1997; 101: 927-947.
31. Roberts AB, Sporn MB: The transforming growth factor-βs; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology. Heidelberg, Springer, 1990, vol 95, pp 419-472.
32. Tripathi RC, Li J, Chan WF, Tripathi BJ: Aqueous humor in glaucomatous eyes contains an elevated level of TGF- β 2. Exp Eye Res 1994; 59: 723-728.
33. Picht G, Welge-Luessen U, Grehn F, Lutjen- Drecoll E: Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol 2001; 239: 199-207.
34. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y: Transforming growth factor- beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol 2001; 239: 109-113.
35. Ochiai Y, Ochiai H: Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol 2002; 46: 249-253.
36. Ozcan AA, Ozdemir N, Canataroglu A: The aqueous levels of TGF- β 2 in patients with glaucoma. Int Ophthalmol 2004; 25: 19-22.
37. Min SH, Lee TI, Chung YS, Kim HK: Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol 2006; 20: 162-165.
38. Schlötzer-Schrehardt U, Zenkel M, Küchle M, Sakai LY, Naumann GOH: Role of transforming growth factor-β 1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 2001; 73: 765-780.
39. Koliakos GG, Schlötzer-Schrehardt R, Konstas AGP, Bufidis T, Georgiadis N, Dimitriadou A: Transforming and insulin-like growth factors in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol 2001; 239: 482-487.
40. Yu XB, Sun XH, Dahan E, Guo W, Qian SH, Meng FR, Song YL, Simon GJB: Increased Levels of transforming growth factor-Beta1 and -Beta2 in the aqueous humor of patients with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2007; 38: 6-14.
41. Fleenor DL, Shepard AR, Helberg PE, Jacobson N, Pang IH, Clark AF: TGF- β 2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci 2006; 47: 226-234.
42. Welge-Lüssen U, May CA, Lütjen-Drecoll E: Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2. Invest Ophthalmol Vis Sci 2000; 41: 2229-2238.
43. Zhao X, Ramsey KE, Stephan DA, Russell P: Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-β . Invest Ophthalmol Vis Sci 2004; 45: 4023-4034.
44. Gottanka J, Chan D, Eichhorn M, Lütjen-Drecoll E, Ross Ethier C: Effects of TGF- β 2 in perfused human eyes. Invest Ophthalmol Vis Sci 2004; 45: 153-158.
45. Baramova E, Foidart J-M: Matrix metalloproteinase family. Cell Biol Int 1995; 19: 239-242.
46. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR: Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21: 75-80.
47. Clark AF: New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci 1998; 39: 2514-2516.
48. Lukes A, Mun Bryce S, Lukes M, Rosenberg GA: Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999; 19: 267-284.
49. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS, Samples JR, Acott TS: Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci 1998; 39: 2649-2658.
50. Acott TS: Biochemistry of aqueous humor outflow; in Kaufman P, Mittag T (eds): Textbook of Ophthalmology. London, Mosby, 1994, vol 7, pp 1.47-41.78.
51. Reynolds JJ: Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis 1996; 2: 70-76.
52. WuDunn D: The effect of mechanical strain on matrix metalloproteinase production by bovine trabecular meshwork cells. Curr Eye Res 2001; 22: 394-397.
53. Rohen JW, Witmer R: Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1972; 183: 251-266.
54. Rohen JW, Futa R, Lutjen-Drecoll E: The fine structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest Ophthalmol Vis Sci 1981; 21: 574-585. (Pubitemid 11031062)
55. Lutjen-Drecoll E, Rohen JW: Morphology of aqueous outflow pathways in normal and glaucomatous eyes; in Ritch R, Shields M, Krupin T (eds): The Glaucomas. St. Louis, Mosby, 1996, vol 1, pp 89-124.
56. Alexander JP, Samples JR, Van Buskirk EM, Acott TS: Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991; 32: 172-180.
57. Samples JR, Alexander JP, Acott TS: Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci 1993; 34: 3386-3395.
58. Acott TS: Trabecular extracellular matrix regulation; in Drance SM, Van Buskirk EM, Neufeld AH (eds): Pharmacology of Glaucoma. Baltimore, Williams and Wilkins, 1992, pp 125-127.
59. Acott TS, Wirtz MK: Biochemistry of aqueous outflow; in Ritch R, Shields M, Krupin T (eds): The Glaucomas. St. Louis, Mosby, 1996, vol 1, pp 281-305.
60. Orengo-Nania S: TGF- β 2 concentration in the aqueous humor of patients with glaucoma and cataract. Inv Ophthalmol Vis Sci 1996; 37(suppl):S27.
61. Katsuta H: Transforming growth factorβ2 in aqueous humor is increased in eyes with primary open angle glaucoma, but not with pseudoexfoliation syndrome and primary angle closure glaucoma. Inv Ophthalmol Vis Sci 1998; 39(suppl):S482.
62. Kinoshita T, Sato H, Takino T, Itoh M, Akizawa T, Seiki M: Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 1996; 56: 2535-2538.
63. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase: isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995: 270: 5331-5338.
64. Okumura Y, Sato H, Seiki M, Kido H: Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin: a possible cell surface activator. FEBS Lett 1997; 402: 181-184.
65. Rondeau E, Sraer J, Schleuning W: The renal plasminogen activating system; in Schlondorff D, Bonventre J (eds): Molecular Nephrology: Kidney Function in Health and Diseases. New York, Marcel Dekker, 1995, pp 699-715.
66. Eitzman DT, Ginsburg D: Of mice and men: the function of plasminogen activator inhibitors (PAIs) in vivo. Adv Exp Med Biol 1997; 425: 131-141.
67. Blasi F: Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u- PA-u-PAR-PAI-1 system. Thromb Haemos 1999; 82: 298-304.
68. Fuchshofer R, Yu AH, Welge-Lüssen U, Tamm ER: Bone morphogenetic protein-7 is an antagonist of transforming growth factor- beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007; 48: 715-726.
69. Wordinger RJ, Fleenor DL, Hellberg PE, Pang IH, Tovar TO, Zode GS, Fuller JA, Clark AF: Effects of TGF- β 2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest Ophthalmol Visual Sci 2007; 48: 1191-1200.
70. Bhattacharya SK, Rockwood EJ, Smith SD, Bonilha VL, Crabb JS, Kuchtey RW, Robertson NG, Peachey NS, Morton CC, Crabb JW: Proteomics reveals cochlin deposits associated with glaucomatous trabecular meshwork. J Biol Chem 2005; 280: 6080-6084.
71. Tripathi RC, Li J, Borisuth NS, Tripathi BJ: Trabecular cells of the eye express messenger RNA for transforming growth factor-beta 1 and secrete this cytokine. Invest Ophthalmol Vis Sci 1993; 34: 2562-2569.
72. Liton PB, Liu X , Challa P , Epstein DL, Gonzalez P: Induction of TGF-beta1 in the trabecular meshwork under cyclic mechanical stress. J Cell Physiol 2005; 205: 364-371. (Pubitemid 41598850)
73. Kirwan RP, Crean JK, Fenerty CH, Clark AF, O'Brien CJ: effect of cyclical mechanical stretch and exogenous transforming growth factor-[beta]1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J Glaucoma 2004; 13: 327-334.
74. Li J, Tripathi BJ, Chalam KV, Tripathi RC: Transforming growth factor-beta 1 and - beta 2 positively regulate TGF-beta 1 mRNA expression in trabecular cells. Invest Ophthalmol Vis Sci 1996; 37: 2778-2782.
75. Zhao X, Ramsey KE, Stephan DA, Russell P: Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest Ophthalmol Vis Sci 2004; 45: 4023-4034.
76. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW: Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005; 46: 908-919.
77. Khalil N: TGB-beta: from latent to active. Microbes Infect 1999; 1: 1255-1263.
78. Massague J: TGF- β signal transduction. Annu Rev Biochem 1998; 67: 753-791.
79. Shi Y, Massague J: Mechanisms of TGF-signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
80. Ten Dijke P, Goumans MJ, Itoh F, Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191: 1-16.
81. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
82. Hershenson MB, Naureckas ET, Li J: Mitogen- activated signaling in cultured airway smooth muscle cells. Can J Physiol Pharmacol 1997; 75: 898-910.
83. Whitmarsh AJ, Davis RJ: Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996; 74: 589-607.
84. Mulder KM, Morris SL: Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem 1992; 267: 5029-5031.
85. Yan Z, Winawer S, Friedman E: Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994; 269: 13231-13237.
86. Hartsough ME, Mulder KM: Transforming growth factor- activation of p44 mapk in proliferating cultures of epithelial cells. J Biol Chem 1995; 270: 7117-7124.
87. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008; 31: 918-924.
88. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, Buttmann M, Grehn F, Schlunck G, Knaus P: p38 Inhibitors prevent TGF- β -induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci 2006; 47: 1500-1509.
89. Cao Y, Wei H, Pfaffl M, Da B: Effect of transforming growth factor beta 2 on phagocytosis in cultured bovine trabecular meshwork cells. Ophthalmologe 2003; 100: 535-538.
90. Cao Y, Wei H, Pfaffl M, Da B, Li Z: Apoptosis of human trabecular meshwork cells induced by transforming growth factor-beta2 in vitro. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 87-89, 94.
91. Qi W, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA: Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006; 69: 989-995.
92. Campistol JM, Iñigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, Rivera F: Losartan decreases plasma levels of TGF-1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719. DOI: 10.1046/j.1523-1755.1999.00597.
93. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M: Peroxisome proliferatoractivated receptor-gamma ligands inhibit TGF-beta1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004; 53: 200-208.
94. Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-ß pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1-11.
95. Zhang S, Shiels IA, Ambler JS, Taylor SM: Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aus NZ J Ophthalmol 1998; 26:S74-S76.
96. Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforming growth factor- gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. Pharmacol Exp Ther 1999; 291: 367-373. (Pubitemid 29451612)
97. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M: Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996; 52: 1057-1063.
98. Ziyadeh FN, Hoffman BB, Han DC, Iglesias- De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci 2000; 97: 8015-8020.
99. McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163: 5693-5699.
100. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, Uchida C, Aoki M, Hosono M, Kitagawa M, Hishida A: Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004; 65: 63-74.
101. Juárez P, Vilchis-Landeros MM, Ponce-Coria J, Mendoza V, Hernández-Pando R, Bobadilla NA, López-Casillas F: Soluble betaglycan reduces renal damage progression in db/db mice. Am J Physiol Renal Physiol 2007; 292:F321-F329.
102. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT: Evaluation of anti-TGFbeta2 antibody as a new postoperative antiscarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003; 44: 3394-3401.
103. Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, Kim KH, Jeon JP, Lee TS, Oh HK, Lee YS, Park KK: TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006; 81: 48-54.
104. Liu FY, Xiao L, Peng YM, Duan SB, Liu H, Liu YH, Ling GH, Yuan F, Chen JX, Fu X, Zhu JL: Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of vascular endothelial growth factor and connective tissue growth factor in cultured human peritoneal mesothelial cells. Chin Med J (Engl) 2007; 120: 231-236.
105. Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ: Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008; 73: 705-715.
106. Saika S, Yamanaka O, Nishikawa-Ishida I, Kitano A, Flanders KC, Okada Y, Ohnishi Y, Nakajima Y, Ikeda K, et al.: Effect of Smad7 gene overexpression on transforming growth factor beta-induced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model. Arch Ophthalmol 2007; 125: 647-654.
107. Lan HY: Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008; 13: 4984-4992.
108. Cui Q, Lim SK, Zhao B, Hoffmann FM: Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene 2005; 24: 3864-3874.
109. Streilein JW, Wilbanks GA, Cousins SW: Immunoregulatory mechanisms of the eye. J Neuroimmunol 1992; 39: 185-200.
110. Streilein JW: Occular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003; 74: 179-185.